Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sumatriptan does not affect vasopressin secretion in humans

T Barreca1, R Franceschini, A Cataldi

  • 1Department of Internal Medicine, University of Genoa, Italy.

Clinical Neuropharmacology
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Liposomes embedded with differentiating factors as a new strategy for enhancing DPSC osteogenic commitment.

European cells & materials·2021
Same author

Liposome-induced exfoliation of graphite to few-layer graphene dispersion with antibacterial activity.

Journal of materials chemistry. B·2020
Same author

BoLA-DRB3 exon2 polymorphisms among tuberculous cattle: Nucleotide and functional variability and their association with bovine tuberculosis pathology.

Research in veterinary science·2020
Same author

A one-year longitudinal study of enterohemorrhagic Escherichia coli O157 fecal shedding in a beef cattle herd.

Research in veterinary science·2019
Same author

First Report of Fusarium Wilt on Hebe sp. in Italy and Europe.

Plant disease·2019
Same author

First Report of the Presence of Albugo tragopogonis on Cineraria maritima in Italy.

Plant disease·2019

Sumatriptan, a serotonin drug, did not affect arginine vasopressin secretion in humans. This suggests that the serotonin receptor targeted by sumatriptan is not involved in regulating vasopressin levels.

Area of Science:

  • Neuroendocrinology
  • Pharmacology

Background:

  • Arginine vasopressin (AVP) plays a crucial role in regulating bodily fluid balance and blood pressure.
  • Serotonergic pathways are known to influence the secretion of various hormones, including AVP.

Purpose of the Study:

  • To investigate the effect of sumatriptan, a selective serotonin receptor agonist, on arginine vasopressin secretion in healthy human volunteers.
  • To determine if the serotonin receptor targeted by sumatriptan is involved in the modulation of AVP release.

Main Methods:

  • Eight healthy male volunteers participated in a double-blind, placebo-controlled study.
  • Plasma AVP concentrations were measured before and after the administration of 6 mg sumatriptan or placebo.
  • A crossover design was employed to compare the effects of sumatriptan and placebo.

Related Experiment Videos

Main Results:

  • Administration of sumatriptan did not result in any significant changes in plasma vasopressin levels.
  • Placebo administration also did not alter vasopressin concentrations.
  • No statistically significant difference was observed in AVP levels between the sumatriptan and placebo conditions.

Conclusions:

  • The findings suggest that the specific serotonin receptor activated by sumatriptan is not implicated in the regulation of arginine vasopressin secretion in humans.
  • Serotonergic mechanisms modulating vasopressin secretion likely involve different serotonin receptor subtypes.
  • Further research may be needed to elucidate the precise serotonergic pathways controlling vasopressin release.